🚀 VC round data is live in beta, check it out!
BioHarvest Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for BioHarvest Sciences and similar public comparables like Omer-Decugis, NWF Group, Orior, Apetit and more.
BioHarvest Sciences Overview
About BioHarvest Sciences
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. This company is the industrial large-scale plant cell growth technology capable of directly and constantly producing active plant ingredients without the necessity to grow the plant itself. The company is focused on leveraging its botanical synthesis technology to develop the next generation of science-based and clinical therapeutic solutions, within two business verticals - nutraceutical health and wellness products such as dietary supplements, and the development of plant cell-based Active Pharmaceutical Ingredients (APIs) that focus on specific medical indications.
Founded
2013
HQ
Employees
87
Website
Sectors
Financials (LTM)
EV
$102M
BioHarvest Sciences Financials
BioHarvest Sciences reported last 12-month revenue of $37M and negative EBITDA of ($3M).
In the same LTM period, BioHarvest Sciences generated $23M in gross profit, ($3M) in EBITDA losses, and had net loss of ($9M).
Revenue (LTM)
BioHarvest Sciences P&L
In the most recent fiscal year, BioHarvest Sciences reported revenue of $25M and EBITDA of ($6M).
BioHarvest Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $37M | XXX | $25M | XXX | XXX | XXX |
| Gross Profit | $23M | XXX | $14M | XXX | XXX | XXX |
| Gross Margin | 61% | XXX | 55% | XXX | XXX | XXX |
| EBITDA | ($3M) | XXX | ($6M) | XXX | XXX | XXX |
| EBITDA Margin | (7%) | XXX | (23%) | XXX | XXX | XXX |
| EBIT Margin | (13%) | XXX | (28%) | XXX | XXX | XXX |
| Net Profit | ($9M) | XXX | ($13M) | XXX | XXX | XXX |
| Net Margin | (25%) | XXX | (51%) | XXX | XXX | XXX |
| Net Debt | — | — | $2M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
BioHarvest Sciences Stock Performance
BioHarvest Sciences has current market cap of $95M, and enterprise value of $102M.
Market Cap Evolution
BioHarvest Sciences' stock price is $4.20.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $102M | $95M | 0.0% | XXX | XXX | XXX | $-0.57 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBioHarvest Sciences Valuation Multiples
BioHarvest Sciences trades at 2.7x EV/Revenue multiple, and (38.9x) EV/EBITDA.
EV / Revenue (LTM)
BioHarvest Sciences Financial Valuation Multiples
As of March 19, 2026, BioHarvest Sciences has market cap of $95M and EV of $102M.
Equity research analysts estimate BioHarvest Sciences' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BioHarvest Sciences has a P/E ratio of (10.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $95M | XXX | $95M | XXX | XXX | XXX |
| EV (current) | $102M | XXX | $102M | XXX | XXX | XXX |
| EV/Revenue | 2.7x | XXX | 4.0x | XXX | XXX | XXX |
| EV/EBITDA | (38.9x) | XXX | (17.5x) | XXX | XXX | XXX |
| EV/EBIT | (21.3x) | XXX | (14.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 4.5x | XXX | 7.3x | XXX | XXX | XXX |
| P/E | (10.2x) | XXX | (7.4x) | XXX | XXX | XXX |
| EV/FCF | (10.3x) | XXX | (10.7x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified BioHarvest Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
BioHarvest Sciences Margins & Growth Rates
BioHarvest Sciences' revenue in the last 12 month grew by 38%.
BioHarvest Sciences' revenue per employee in the last FY averaged $0.4M.
BioHarvest Sciences' rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BioHarvest Sciences' rule of X is 88% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
BioHarvest Sciences Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 38% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Margin | (7%) | XXX | (23%) | XXX | XXX | XXX |
| EBITDA Growth | (227%) | XXX | (35%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 31% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 88% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 44% | XXX | 37% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 15% | XXX | 26% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 15% | XXX | 19% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 83% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
BioHarvest Sciences Public Comps
See public comps and valuation multiples for other Food & Beverages comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Omer-Decugis | XXX | XXX | XXX | XXX | XXX | XXX |
| NWF Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Orior | XXX | XXX | XXX | XXX | XXX | XXX |
| Apetit | XXX | XXX | XXX | XXX | XXX | XXX |
| Zevia | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BioHarvest Sciences M&A Activity
BioHarvest Sciences acquired XXX companies to date.
Last acquisition by BioHarvest Sciences was on XXXXXXXX, XXXXX. BioHarvest Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by BioHarvest Sciences
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBioHarvest Sciences Investment Activity
BioHarvest Sciences invested in XXX companies to date.
BioHarvest Sciences made its latest investment on XXXXXXXX, XXXXX. BioHarvest Sciences invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by BioHarvest Sciences
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout BioHarvest Sciences
| When was BioHarvest Sciences founded? | BioHarvest Sciences was founded in 2013. |
| Where is BioHarvest Sciences headquartered? | BioHarvest Sciences is headquartered in United States. |
| How many employees does BioHarvest Sciences have? | As of today, BioHarvest Sciences has over 87 employees. |
| Who is the CEO of BioHarvest Sciences? | BioHarvest Sciences' CEO is Ilan Sobel. |
| Is BioHarvest Sciences publicly listed? | Yes, BioHarvest Sciences is a public company listed on Nasdaq. |
| What is the stock symbol of BioHarvest Sciences? | BioHarvest Sciences trades under BHST ticker. |
| When did BioHarvest Sciences go public? | BioHarvest Sciences went public in 2019. |
| Who are competitors of BioHarvest Sciences? | BioHarvest Sciences main competitors are Omer-Decugis, NWF Group, Orior, Apetit. |
| What is the current market cap of BioHarvest Sciences? | BioHarvest Sciences' current market cap is $95M. |
| What is the current revenue of BioHarvest Sciences? | BioHarvest Sciences' last 12 months revenue is $37M. |
| What is the current revenue growth of BioHarvest Sciences? | BioHarvest Sciences revenue growth (NTM/LTM) is 38%. |
| What is the current EV/Revenue multiple of BioHarvest Sciences? | Current revenue multiple of BioHarvest Sciences is 2.7x. |
| Is BioHarvest Sciences profitable? | No, BioHarvest Sciences is not profitable. |
| What is the current EBITDA of BioHarvest Sciences? | BioHarvest Sciences has negative EBITDA and is not profitable. |
| What is BioHarvest Sciences' EBITDA margin? | BioHarvest Sciences' last 12 months EBITDA margin is (7%). |
| What is the current EV/EBITDA multiple of BioHarvest Sciences? | Current EBITDA multiple of BioHarvest Sciences is (38.9x). |
| What is the current FCF of BioHarvest Sciences? | BioHarvest Sciences' last 12 months FCF is ($10M). |
| What is BioHarvest Sciences' FCF margin? | BioHarvest Sciences' last 12 months FCF margin is (26%). |
| What is the current EV/FCF multiple of BioHarvest Sciences? | Current FCF multiple of BioHarvest Sciences is (10.3x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.